Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Valby, Denmark, 16 February 2024 - H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.
+--+-----------------+--------------+----------------+
|1.|Details of the |
| |person |
| |discharging |
| |managerial |
| |responsibilities |
| |/ person closely |
| |associated |
+--+-----------------+--------------+----------------+
|a)|Name |Joerg Hornstein |
+--+-----------------+--------------+----------------+
|2.|Reason for the |
| |notification |
+--+-----------------+--------------+----------------+
|a)|Position/status |Executive Vice |
| | |President & CFO |
+--+-----------------+--------------+----------------+
|b)|Initial |Initial notification |
| |notification/Amen| |
| |dment | |
+--+-----------------+--------------+----------------+
|3.|Details of the |
| |issuer, |
| |emission |
| |allowance |
| |market |
| |participant, |
| |auction |
| |platform, |
| |auctioneer or |
| |auction monitor |
+--+-----------------+--------------+----------------+
|a)|Name |H. Lundbeck A/S |
+--+-----------------+--------------+----------------+
|b)|LEI code |5493006R4KC2OI5D3470 |
+--+-----------------+--------------+----------------+
|4 |Details of the |
| |transaction(s): |
| |section to be |
| |repeated for (i) |
| |each type of |
| |instrument; (ii) |
| |each type of |
| |transaction; |
| |(iii) each date; |
| |and (iv) each |
| |place where |
| |transactions |
| |have been |
| |conducted |
+--+-----------------+--------------+----------------+
|a)|Description of |SharesH. Lundbeck |
| |the financial |A/S, B-shares: |
| |instrument, type |DK0061804770 |
| |of instrument | |
| |Identification | |
| |code | |
+--+-----------------+--------------+----------------+
|b)|Nature of the |Purchase of shares |
| |transaction | |
+--+-----------------+--------------+----------------+
|c)|Price(s) and |Price(s) |Volume(s) |
| |volume(s) | | |
+--+-----------------+--------------+----------------+
| | |DKK 33.32 (B|B-shares: 22,529|
| | |-shares) | |
+--+-----------------+--------------+----------------+
|d)|Aggregated | |
| |information | |
| |- Aggregated | |
| |volume | |
| |- Price | |
+--+-----------------+--------------+----------------+
|e)|Date of the |2024-02-15 |
| |transaction | |
+--+-----------------+--------------+----------------+
|f)|Place of the |NASDAQ Copenhagen |
| |transaction |XCSE |
+--+-----------------+--------------+----------------+Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.
Closely associated persons/entities means inter alia:
- spouse or cohabitant
- dependent children
- legal entities in which the executive has a controlling influence
Lundbeck contacts
Investors: Media:
Palle Holm Olesen Thomas Mikkel
Mortensen
Vice President, Investor Relations Media Relations Lead,
Corporate
Communication
PALO@lundbeck.com THMR@lundbeck.com
+45 30 83 24 26 +45 30 83 30 24
Sophia Nørskov Bech
Senior Manager, Investor Relations
SONQ@lundbeck.com
+45 30 83 24 60
About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focused exclusively on neuroscience, with more than 70 years of experience in improving the lives of people with neurological and psychiatric diseases. As a focused innovator, we strive for our research and development programs to tackle some of the most complex challenges. We develop transformative medicines targeting people for whom there are few, if any, treatment options. Our goal is to create long term value and make a positive contribution to people and societies, everywhere we operate. We are committed to fighting stigma and discrimination, and we act to improve health equity for the people we serve and the communities we are part of.
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.
Safe Harbor/Forward-Looking Statements
This corporate release contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe", "anticipate", "expect", "estimate", "intend", "plan", "project", "will be", "will continue", "will result", "could", "may", "might", or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements.
Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Factors that may affect future results include, among others, interest rate and currency exchange rate fluctuations, delay or failure of development projects, production or distribution problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.
The forward-looking statements in this document and oral presentations made on behalf of Lundbeck speak only as at the date of this presentation. Lundbeck does not undertake any obligation to update or revise forward-looking statements in this presentation or oral presentations made on behalf of Lundbeck, nor to confirm such statements to reflect subsequent events or circumstances after the date of the presentation or in relation to actual results, unless otherwise required by applicable law or applicable stock exchange regulations.